
Reduced Prostaglandin D₂ Production by Airway Fibroblasts in Nonsteroidal Anti-inflammatory Drug-Exacerbated Airway Disease

Roca-Ferrer J^{1,2}, Machado-Carvalho L^{3,4}, Picado C^{1,2}

¹*Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain*

²*Centro de Investigaciones en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain*

³*Department of Biology and Environment, School of Life Sciences and Environment, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal.*

⁴*Center for Research and Technology of Agro-Environmental and Biological Sciences (CITAB-UTAD), University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal*

J Investig Allergol Clin Immunol 2025; Vol. 35(4)
doi: 10.18176/jiaci.1062

Key words: Asthma. Aspirin. N-ERD. Prostaglandin E₂. Prostaglandin D₂.

Palabras clave: Asma. Aspirina. N-ERD. Prostaglandina E₂. Prostaglandina D₂.

Nonsteroidal anti-inflammatory drug (NSAID)–exacerbated airway disease (N-ERD) is caused by a nonallergic hypersensitivity reaction precipitated by aspirin and other NSAIDs. N-ERD is clinically characterized by the co-occurrence of asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). There is evidence that N-ERD is associated with the dysregulation of arachidonic acid (AA) metabolism [1].

AA is mobilized from membrane phospholipids by phospholipases and is converted by cyclooxygenases (COX) into prostaglandin H₂, which is subsequently metabolized to prostaglandins (PGs), thromboxanes, and prostacyclin, with the contribution of specific synthases. There are 2 COX isoforms: COX-1 and COX-2. COX-1 is constitutively expressed, while COX-2 is induced, and its expression increases markedly under inflammatory conditions. AA is also catalyzed by 5-lipoxygenase (5-LO) to generate cysteinyl leukotrienes (CysLTs) [1].

Reduced synthesis of prostaglandin E₂ and overproduction of prostaglandin D₂ (PGD₂) and CysLTs are characteristic of N-ERD. Elevated levels of leukotriene E₄ and PGD₂ are observed at baseline in different body fluids (nasal, bronchial, and urine samples). Following ingestion of aspirin and other NSAIDs, COX-1 inhibition decreases the biosynthesis of PGE₂ but enhances the release of CysLTs and PGD₂, both of which are responsible for upper airway symptoms (nasal congestion, nasal discharge) and lower airway symptoms (bronchoconstriction). In contrast, selective COX-2 inhibitors are well tolerated [1].

PGE₂ reduces the activity of 5-LO, resulting in reduced CysLT production [2], and inhibits the production of thymic stromal lymphopoietin, the cytokine involved in PGD₂ production by mast cells and eosinophils [3]. It is commonly accepted that the impaired PGE₂ synthesis in N-ERD accounts for the excessive production of both CysLTs and PGD₂ at baseline. The further reduction in PGE₂ synthesis by NSAIDs contributes to the surge in CysLTs and release of PGD₂, which result in exacerbated airway disease [1].

One of the intriguing observations in N-ERD is the dissociated production of PGE₂ and PGD₂, 2 prostanoids with a common COX metabolic pathway [1]. Reduced PGE₂ production has been reported in airway fibroblasts and epithelial cells associated with diminished expression of inducible COX-2 [4-6]. It was recently suggested that low PGE₂ production would contribute to excessive release of alarmins such as TLSP from airway cells. This, in turn, would increase the metabolic activity of the COX pathway, thereby increasing PGD₂ production by mast cells and eosinophils [7].

If this observation in inflammatory cells is applied to the respiratory epithelium of patients with N-ERD, we would expect that, via an autoregulatory mechanism, the excessive production of thymic stromal lymphopoietin would also increase the activity of the COX pathway in the epithelium, leading to increased synthesis of the prostanoids PGE₂ and PGD₂ in epithelial cells. As mentioned above, this is not the case for PGE₂, whose production is reduced [4-6]. However, very little is known about the regulation of PGD₂ in the structural cells of the respiratory epithelium; only 1 previous study reported deficient production of PGD₂ in nasal polyp fibroblasts from N-ERD patients with respect to healthy controls [5].

Our study hypothesizes that, in the respiratory epithelium (fibroblasts, epithelial cells) of patients with N-ERD, there is an intrinsic alteration of the COX pathway, particularly COX-2. This reduces its capacity for prostanoid synthesis, impacting the production of both PGE₂ and PGD₂.

To prove this hypothesis, we performed a dynamic analysis of PGD₂ production in cultured fibroblasts from nasal mucosa (control group) and nasal polyps from N-ERD and non-N-ERD patients. The online supplementary file shows the demographic and clinical characteristics of the study population, as well as information regarding cell culture, the experimental protocol, analysis, and statistics. All the patients provided their informed consent to participate in the study, which was approved by the local scientific and ethics committee.

As previously reported for PGE₂, control of nasal mucosa fibroblasts incubated with IL-1 β revealed statistically significant increased production of PGD₂ after 24 hours of incubation (5-fold increase). This cytokine only induced a mild, statistically significant increase in PGD₂ production in non-N-ERD patients at 24 hours (2-fold increase) and no change in N-ERD patients (Figure). This pattern of




Figure. Time course of IL-1 β in secretion of PGD₂ protein. Supernatants were obtained from 150-cm² flasks containing quiescent fibroblast cultures incubated for 4 to 24 hours with serum-free media in the presence or absence of 10 ng/mL IL-1 β and normalized to the total protein content in cell lysates from the corresponding samples. PGD₂ concentrations were measured using ELISA. Statistically significant difference ($P < .05$) at 24 hours with respect to the baseline value in control NM. Statistically significant difference ($P < .05$) at 24 hours with respect to 4 hours in non-N-ERD. NM indicates nasal mucosa; N-ERD, nonsteroidal anti-inflammatory drugs-exacerbated airway disease.

IL-1 β -induced PGD₂ expression in fibroblasts mimics that previously observed for PGE₂, supporting the hypothesis that there is an intrinsic anomaly in the regulation of the COX-2 pathway in N-ERD fibroblasts, resulting in deficient production of all prostanoids. Of note, the induction of COX-2 and the subsequent release of prostanoids is also disturbed, albeit to a lesser extent, in NSAID-tolerant individuals [6,8]. It remains unclear whether there is a threshold below which NSAID intolerance develops or whether other, yet unknown cofactors contribute to N-ERD.

While the mechanisms underlying disturbed AA metabolism have yet to be fully elucidated, previous studies demonstrated that the combined action of IL-4, a T_H2 cytokine, and INF- γ , a T_H1 cytokine, can induce disturbances in AA metabolism in healthy nasal mucosa that are similar to those arising spontaneously in N-ERD [9,10].

Our study is limited by the low number of patients included, thus explaining the lack of statistically significant differences between some values. Nasal polyps are usually removed from patients with a poor response to therapy and, therefore, tend to represent the most severe cases. In addition, given that severity may have an impact on AA metabolism, the results obtained should be demonstrated in milder cases.

In summary, our findings support the notion that the disrupted COX-2 pathway, together with the associated reduction in prostanoid production, is primarily localized in the airway epithelium, while inflammatory cells such as mast cells and eosinophils escape this anomaly. Gaining a deeper understanding of the role of the airway epithelium could afford valuable insights into the mechanisms underlying N-ERD.

Funding

The authors declare that no funding was received for the present study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

1. Taniguchi M, Mitsui C, Hayashi H, Ono E, Kajiwara K, Mita H, et al. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD. *Allergol Int.* 2019;68:289-95.
2. Rusznak M, Peebles RS Jr. Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells. *Curr Opin Allergy Clin Immunol.* 2019;19:38-45.
3. Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol.* 2016;137:1566-76.
4. Pierzchalska M, Soja J, Woś M, Szabó Z, Nizankowska-Mogielnicka E, Sanak M, et al. Deficiency of cyclooxygenases transcripts in cultured primary bronchial epithelial cells of aspirin-sensitive asthmatics. *J Physiol Pharmacol.* 2007;58:207-18.
5. Pierzchalska M, Szabó Z, Sanak M, Soja J, Szczeklik A. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. *J Allergy Clin Immunol.* 2003;111:1041-8.
6. Roca-Ferrer J, Garcia-Garcia FJ, Pereda J, Perez-Gonzalez M, Pujols L, Alobid I, et al. Reduced expression of COXs and production of prostaglandin E2 in patients with nasal polyps with or without aspirin-intolerant asthma. *J Allergy Clin Immunol.* 2011;128:66-72.
7. Picado C, Machado-Carvalho L, Roca-Ferrer J. Low prostaglandin E2 but high prostaglandin D2, a paradoxical dissociation in arachidonic acid metabolism in aspirin-exacerbated airway disease: Role of airway epithelium. *J Clin Med.* 2024;13:7416.
8. Pujols L, Mullol J, Alobid I, Roca-Ferrer J, Xaubet A, Picado C. Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. *J Allergy Clin Immunol.* 2004;114:814-9.
9. Hayashi Y, Kobayashi M, Kuwata H, Atsumi G, Deguchi K, Feng Wei X, et al. In-terferon-gamma and interleukin 4 inhibit interleukin 1-beta-induced delayed prostaglandin E2 generation through suppression of cyclooxygenase-2 expression in human fibroblasts. *Cytokine.* 2000;12:603-12.
10. Machado-Carvalho L, Roca-Ferrer J, Picado C. IL-4/IFN- γ inflammatory cytokine profile induces a deficient regulation of the IL-1 β /IL-1R1/EP2/COX-2 pathway in nasal mucosa. *Respir Med.* 2019;150:136-40.

■ Manuscript received December 19, 2024; accepted for publication January 15, 2025.

César Picado
CELEX

Facultat de Medicina, Primer Pis
Villarroel 170
08035 Barcelona
E-mail: cpicado@ub.edu